EP0625149A1 - Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists - Google Patents

Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Info

Publication number
EP0625149A1
EP0625149A1 EP93917412A EP93917412A EP0625149A1 EP 0625149 A1 EP0625149 A1 EP 0625149A1 EP 93917412 A EP93917412 A EP 93917412A EP 93917412 A EP93917412 A EP 93917412A EP 0625149 A1 EP0625149 A1 EP 0625149A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
compound according
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93917412A
Other languages
German (de)
French (fr)
Inventor
Francis David King
Laramie Mary Gaster
Graham Francis Joiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929202510A external-priority patent/GB9202510D0/en
Priority claimed from GB929215499A external-priority patent/GB9215499D0/en
Priority claimed from GB929221446A external-priority patent/GB9221446D0/en
Priority claimed from GB929225788A external-priority patent/GB9225788D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0625149A1 publication Critical patent/EP0625149A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to the use of compounds as 5-HT 4 receptor antagonists in the treatment of gastrointestinal disorders, CNS disorders including migraine and/or cardiovascular disorders, and to certain novel compounds having 5-HT 4 receptor antagonist activity.
  • EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT 4 antagonist activity.
  • 5-HT 3 receptor antagonists have been disclosed as of potential use in the treatment of certain aspects of irritable bowel syndrome [EP-A-189002 (Sandoz Limited) and EP-A-201165 (Beecham Group p.l.c)].
  • 5-HT 3 receptor interactions which are of potential use in the treatment of IBS are those associated either with the visceral pain and abnormal perception of sensation aspects of this disease, or they are related to the ability of some 5- HT 3 receptor antagonists to cause constipation in volunteers.
  • 5-HT 3 receptor antagonists have been disclosed as of potential use in the treatment of gastrointestinal disorders associated with upper gut motility [EP-A-226266 (Glaxo Group Ltd.) and EP-A-189002 (Sandoz Limited)].
  • 5-HT 3 receptor antagonists are also well known antiemetics, such as ondansetron, granisetron and tropisetron [Drugs of the Future 1989, 14 (9) p.875 - F.D. King and G.J. Sanger].
  • EP-A-234872 (Adria), US 4859683 (Rorer) and EP-A-307172 (Lilly) describe 5-HT 3 receptor antagonists derived from a benzoic acid nucleus, 2,3-disubstituted by alkyleneoxy. It has now been discovered that certain of the compounds embraced by the general formulae disclosed therein, and related compounds, have 5-HT 4 receptor antagonist properties, and are therefore of potential use in the treatment of IBS or atrial arrhythmias and stroke.
  • the compounds of the present invention also have a potential use in the treatment of CNS disorders such as anxiety and/or migraine, in the treatment of upper gut motility disorders and as antiemetics.
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • one of X-) and X2 is O, S or CH 2 and the other is CH 2 ;
  • x is 1 , 2 or 3;
  • R 1 is hydrogen, amino, halo, C 1-6 alkyl, hydroxy or C 1-6 alkoxy;
  • R 2 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, nitro, amino or C 1-6 alkylthio;
  • R 3 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy or amino
  • R 4 and R 5 are independently hydrogen or C 1-6 alkyl
  • Y is O or NH
  • Z is of sub-formula (a), (b) or (c):
  • R a is hydrogen or a lipophilic group, such as C 1-12 alkyl or aralkyl; or
  • R a is (CH 2 ) r -R 10 wherein r is 2 or 3 and R 10 is selected from cyano,
  • R 1 1 and R 12 are hydrogen or C 1-6 alkyl
  • R 6 , R 7 and R 8 are independently hydrogen or C 1-6 alkyl
  • R 9 is hydrogen or C 1-10 alkyl
  • alkyl or alkyl containing groups examples include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9t C 10 , C 1 1 or C 12 branched, straight chained or cyclic alkyl, as appropriate.
  • C 1 -4 alkyl groups include methyl, ethyl n- and iso-propyl, n-, iso- , sec- and tert-butyl.
  • Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C 1-6 alkyl and C 1-6 alkoxy.
  • Halo includes fluoro, chloro, bromo and iodo,.
  • a suitable bioisostere for the amide or ester linkage containing Y in formula (I), is of formula (d)
  • H, J and I independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of H, J and I is other than carbon; U represents nitrogen or carbon.
  • Suitable examples of (d) are as described for X, Y and Z in EP-A-328200 (Merck Sharp & Dohme Ltd.), such as an oxadiazole moiety.
  • X 1 -(CH 2 ) 2 -X 2 is O-(CH 2 ) 2 -CH 2 .
  • R 1 is preferably hydrogen or amino.
  • R 2 is preferably hydrogen or halo.
  • R 3 is preferably hydrogen or halo.
  • R 4 and R 5 are often hydrogen. When R 4 /R 5 is C 1-6 alkyl, it is often methyl. In particular R 4 and R 5 are methyl such that the disubstituent containing X 1 and X 2 is X 1 -C(CH 3 ) 2 -X 2 .
  • Y is preferably O or NH.
  • n 1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n 1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
  • n 2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
  • n 3 is preferably 2, 3 or 4.
  • R 8 and R 9 are preferably both alkyl, especially one of R 8 and R 9 is C 4 or larger alkyl.
  • the invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii).
  • the piperidine ring in (i), (ii) or (iii) may be replaced by pyrrolidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C 3 or larger alkyl or optionally substituted benzyl.
  • the N-substituent in formula (i) or (ii) may be replaced by (CH 2 ) n R 4 , as defined in formula(l) and in relation to the specific examples of EP-A-501322.
  • the invention also provides novel compounds within formula (I) having
  • the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1 -phosphoric acids.
  • conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids
  • pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1 -phosphoric acids.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R x -T wherein R x is C 1-6 alkyl, phenyl- C 1-6 alkyl or C 5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R x include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
  • Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
  • the (CH 2 ) n 2 moiety in compounds of formula (I) wherein Z is (b), may adopt an ⁇ or ⁇ or configuration with respect to the fused azabicyclic moiety.
  • the compounds of formula (I) wherein CO-Y is an ester or amide linkage are prepared by conventional coupling of the Z moiety with the appropriate acid. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A, EP-A-36269 and EP-A-289170 (Beecham Group p.l.c). When CO-Y is replaced by a heterocyclic bioisostere, suitable methods are described in EP-A-328200 (Merck Sharp & Dohme Limited). Reference is also made to EP-A-501322 (Glaxo Group Limited).
  • Aza(bi)cyclic side chain intermediates are known compounds or may be prepared according to the methods described in PCT/GB92/01519 and /01612 (SmithKline Beecham p.l.c).
  • the compounds of the present invention are 5-HT 4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
  • IBS irritable bowel syndrome
  • these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
  • Anxiolytic activity is likely to be effected via the hippocampus (Dumais et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test. Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT 4 receptors, and hence that administration of a 5-HT 4 antagonist is of potential benefit in relieving a migraine attack.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Such compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges,
  • reconstitutable powders injectable and infusable solutions or suspensions or suppositories.
  • Orally administrable compositions are preferred, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol;
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • almond oil fractionated coconut oil
  • oily esters such as esters of g
  • preservatives for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • Oral liquid preparations are usually in the form of aqueous or oily
  • suspensions, solutions, emulsions, syrups, or elixirs are presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
  • the oral compositions may be prepared by conventional methods of blending, filling ortabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anodide
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • the invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal.
  • a unit dose for a 70kg adult will normally contain 0.05 to 1000mg for example 0.5 to 500mg, of the compound of the invention.
  • Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastrooesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastrooesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
  • a preferred compound corresponds to any example, but wherein there is an amino substituent in the 4-position and a chloro substituent in the 5-position of the benzoic acid nucleus depicted in formula (I).
  • the residual acid chloride was dissolved in dry THF (20 ml) and added dropwise to a solution of the lithium anion of 1-butyl-4-piperidinemethanol in dry THF, prepared by treating a solution of 1-butyl-4-piperidinemethanol (0.29g) in dry THF (20ml) with butyllithium (1.1 ml of a 1.6 molar solution in hexane), at 0°C under nitrogen for 15 minutes. After stirring at ambient temperature overnight, the reaction mixture was diluted with water, the volatile solvent was evaporated under reduced pressure, and the product was extracted into dichloromethane. The organic phase was dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure.
  • Methyllithium (1.5M in diethyl ether, 0.97 ml) was added dropwise to a cooled (0°C) solution of 1-butyl-4-piperidinemethanol (250 mg) in dry THF (10 ml) under a nitrogen atmosphere. Stirring was continued at room temperature for 10 min. A solution of the imidazolide in dry THF (10ml) was added and stirring continued overnight. Water was added and the solvent concentrated in vacuo. The residue was partitioned between chloroform and water. The organic phase was dried (Na 2 SO 4 ), filtered and concentrated. The residue was chromatographed on silica using chloroform and ethanol as eluant to afford pure ester (471 mg) as an oil.
  • Methylthiochroman-4-one-8-carboxylate (0.500g, 2.25mmol) was dissolved with stirring in ethanol (20 ml). After 1 h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between ethyl acetate and water.
  • Methyl thiochroman-4-ol-8-carboxylate (0.337g, 1.50 mmol) was dissolved in toluene (25ml) and was treated with p-toluenesulphonic acid (0.028g, 0.15 mmol). The mixture was then heated to reflux with stirring. After 2h, the reaction mixture was allowed to cool and was washed with sodium hydrogen carbonate solution.
  • Methyl-2H-thiochromene-8-carboxylate (1.83g, 8.88 mmol) was dissolved in ethanol (100ml) and treated with 10% PdC (1.5g). The mixture was then hydrogenated at atmospheric pressure at room temperature. After 19h the reaction mixture was filtered through celite and evaporated under reduced pressure to give a colourless oil which was dried in vacuo to give the title compound (1.25g, 68%) 1 H NMR (200 MHz, CDCI 3 ), ⁇ 7.80 (d, 1 H), 7.62 (d, 1 H), 6.97 (t, 1 H), 3.89 (s, 3H), 2.97 (t, 2H), 2.87 (t, 2H), 2.12 (m, 2H).
  • guinea-pigs Male guinea-pigs, weighing 250-400g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3cm long, are obtained from the distal colon region. These are suspended under a 0.5g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O 2 and maintained at 37°C. In all experiments, the Krebs solution also contains methiothepin 10 -7 M and granisetron 10 -6 M to block effects at 5-HT 1 , 5-HT 2 and 5-HT 3 receptors.
  • a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 4 70% maximum(10 -9 M approx).
  • the tissue is then alternately dosed every 15min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP).
  • DMPP dimethylphenylpiperazinium
  • increasing concentrations of a putative 5-HT 4 receptor antagonist are then added to the bathing solution.
  • the effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, plC 50 values are determined, being defined as the-log concentration of antagonist which reduces the contraction by 50%.
  • a compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor antagonist.
  • Rat oesophageal tunica muscularis mucosae is set up according to Baxter et. al. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991 ).
  • the inner smooth muscle tube of the muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% 02/5% CO 2 ) Tyrodes solution at 37°C. All experiments are performed in pargyline pre-treated preparations (100 ⁇ M for 15 min followed by washout) and in the presence of ***e (30 ⁇ M). Relaxant responses to 5-HT are obtained after pre-contracting the oesophagus tissue with carbachol (3 ⁇ M).
  • the compound E3 showed inhibition at a dose of 10 ⁇ g kg - 1 .

Abstract

L'invention se rapporte à des composés de la formule (I) et à des sels pharmaceutiquement acceptables de ceux-ci, dans laquelle X1-(CH2)x-X2 et les atomes de carbone aromatiques auxquels ils sont fixés forment un noyau de 5 à 7 éléments dans lequel un élément parmi X1 et X2 représente O, S ou CH2 et l'autre représente CH2; x est 1, 2, ou 3; R1 représente hydrogène, amino, halo, alkyle C1-6, hydroxy ou alcoxy C1-6; R2 représente hydrogène, halo et alkyle C1-6, alcoxy C1-6, nitro, amino ou alkylthio C1-6; R3 représente hydrogène, halo, alkyle C1-6, alcoxy C1-6 ou amino; R4 et R5 représentent indépendamment hydrogène ou alkyle C1-6; Y représente O ou NH; Z représente la sous-formule (a), (b) ou (c), dans laquelle n1 est 1, 2, 3 ou 4; n2 est 1 ou 2; n3 est 2, 3, 4 ou 5; q est 0, 1, 2 ou 3; p est 0, 1 ou 2; m est 0, 1 ou 2; Ra représente hydrogène ou un groupe lipophilee tel qu'alkyle C1-12 ou aralkyle; ou Ra représente (CH2)GAMMAR10 où r est 2 ou 3 et R10 est sélectionné parmi cyano, hydroxyle, alcoxy C1-6, phénoxy, alkyle C(O)C1-6, COC6H5, -CR11R12, NR11COR12, SO2NR11R12 ou NR11SO2R12 où R11 et R12 représentent hydrogène ou alkyle C1-6; et R6, R7 et R8 représentent indépendamment hydrogène ou alkyle C1-6; et R9 représente hydrogène ou alkyle C1-10; ou un composé de la formule (I) dans laquelle la liaison CO-Y est remplacée par un bioisostère hétérocyclique; l'invention se rapporte également à l'utilisation de ces composés comme produits pharmaceutiques dans le traitement de troubles gastro-intestinaux, de troubles cardiovasculaires et de troubles du système nerveux central (SNC).The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein X1- (CH2) x-X2 and the aromatic carbon atoms to which they are attached form a ring of 5 with 7 elements in which one element among X1 and X2 represents O, S or CH2 and the other represents CH2; x is 1, 2, or 3; R1 represents hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy; R2 represents hydrogen, halo and C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio; R3 represents hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino; R4 and R5 independently represent hydrogen or C1-6 alkyl; Y represents O or NH; Z represents the sub-formula (a), (b) or (c), in which n1 is 1, 2, 3 or 4; n2 is 1 or 2; n3 is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2; Ra represents hydrogen or a lipophilic group such as C1-12 alkyl or aralkyl; or Ra represents (CH2) GAMMAR10 where r is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C (O) C1-6 alkyl, COC6H5, -CR11R12, NR11COR12, SO2NR11R12 or NR11SO2R12 where R11 and R12 represent hydrogen or C1-6 alkyl; and R6, R7 and R8 independently represent hydrogen or C1-6alkyl; and R9 represents hydrogen or C1-10 alkyl; or a compound of formula (I) in which the CO-Y bond is replaced by a heterocyclic bioisostere; the invention also relates to the use of these compounds as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and central nervous system (CNS) disorders.

Description

Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
This invention relates to the use of compounds as 5-HT4 receptor antagonists in the treatment of gastrointestinal disorders, CNS disorders including migraine and/or cardiovascular disorders, and to certain novel compounds having 5-HT4 receptor antagonist activity.
European Journal of Pharmacology 146 (1988), 187-188, and Naunyn- Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT4 receptor, and that ICS 205-930, which is also a 5-HT3 receptor antagonist, acts as an antagonist at this receptor. WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT4 antagonist activity.
Some 5-HT3 receptor antagonists have been disclosed as of potential use in the treatment of certain aspects of irritable bowel syndrome [EP-A-189002 (Sandoz Limited) and EP-A-201165 (Beecham Group p.l.c)].
5-HT3 receptor interactions which are of potential use in the treatment of IBS are those associated either with the visceral pain and abnormal perception of sensation aspects of this disease, or they are related to the ability of some 5- HT3 receptor antagonists to cause constipation in volunteers.
Some 5-HT3 receptor antagonists have been disclosed as of potential use in the treatment of gastrointestinal disorders associated with upper gut motility [EP-A-226266 (Glaxo Group Ltd.) and EP-A-189002 (Sandoz Limited)].
5-HT3 receptor antagonists are also well known antiemetics, such as ondansetron, granisetron and tropisetron [Drugs of the Future 1989, 14 (9) p.875 - F.D. King and G.J. Sanger]. EP-A-234872 (Adria), US 4859683 (Rorer) and EP-A-307172 (Lilly) describe 5-HT3 receptor antagonists derived from a benzoic acid nucleus, 2,3-disubstituted by alkyleneoxy. It has now been discovered that certain of the compounds embraced by the general formulae disclosed therein, and related compounds, have 5-HT4 receptor antagonist properties, and are therefore of potential use in the treatment of IBS or atrial arrhythmias and stroke. The compounds of the present invention also have a potential use in the treatment of CNS disorders such as anxiety and/or migraine, in the treatment of upper gut motility disorders and as antiemetics.
Accordingly, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
in which X1-(CH2)x-X2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring
wherein:
one of X-) and X2 is O, S or CH2 and the other is CH2;
x is 1 , 2 or 3;
R 1 is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
R2 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio;
R3 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 and R5 are independently hydrogen or C1-6 alkyl;
Y is O or NH;
Z is of sub-formula (a), (b) or (c):
wherein
n1 is 1 , 2, 3 or 4; n2 is 1 or 2; n3 is 2, 3, 4 or 5;
q is 0, 1 , 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
Ra is hydrogen or a lipophilic group, such as C1-12 alkyl or aralkyl; or
Ra is (CH2)r-R10 wherein r is 2 or 3 and R10 is selected from cyano,
hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6H5, -CR11R 12,
NR1 1COR12, SO2NR1 1 R12 or NR1 1 SO2R12 wnerein R1 1 and R 12 are hydrogen or C1-6 alkyl; and
R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and
R9 is hydrogen or C 1-10 alkyl;
or a compound of formula (I) wherein the CO-Y linkage is replaced by a
heterocyclic bioisostere;
in the manufacture of a medicament for use as a 5-HT4 receptor antagonist.
Examples of alkyl or alkyl containing groups include C1, C2, C3, C4, C5, C6, C7, C8, C9t C10, C1 1 or C12 branched, straight chained or cyclic alkyl, as appropriate. C1 -4 alkyl groups include methyl, ethyl n- and iso-propyl, n-, iso- , sec- and tert-butyl. Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C1-6 alkyl and C1-6 alkoxy.
Halo includes fluoro, chloro, bromo and iodo,.
A suitable bioisostere for the amide or ester linkage containing Y in formula (I), is of formula (d)
wherein
the dotted circle represents one or two double bonds in any position in the 5-membered ring; H, J and I independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of H, J and I is other than carbon; U represents nitrogen or carbon.
Suitable examples of (d) are as described for X, Y and Z in EP-A-328200 (Merck Sharp & Dohme Ltd.), such as an oxadiazole moiety.
Suitable examples of the X1-(CH2)x-X2 include O-(CH2)2-CH2, O-(CH2)3-CH2, O-CH2-CH2, or corresponding values wherein X 1 = X2 = CH2, wherein any of the methylene linkages are optionally mono- or di-substituted by C1-6 alkyl groups, such as methyl. Preferably X1 -(CH2)2-X2 is O-(CH2)2-CH2.
R1 is preferably hydrogen or amino.
R2 is preferably hydrogen or halo.
R3 is preferably hydrogen or halo.
R4 and R5 are often hydrogen. When R4/R5 is C1-6 alkyl, it is often methyl. In particular R4 and R5 are methyl such that the disubstituent containing X1 and X2 is X1 -C(CH3)2-X2.
Y is preferably O or NH.
When Z is of sub-formula (a), n1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
When Z is of sub-formula (b), n2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
Suitable values for p and m include p = m = 1 ; p = 0, m = 1 ; p = 1 , m = 2. When Z is of sub-formula (c), n3 is preferably 2, 3 or 4.
R8 and R9 are preferably both alkyl, especially one of R8 and R9 is C4 or larger alkyl.
Specific values of Z of particular interest are as follows:
( )
The invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii). In a further aspect, the piperidine ring in (i), (ii) or (iii) may be replaced by pyrrolidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C3 or larger alkyl or optionally substituted benzyl. ln an alternative aspect, the N-substituent in formula (i) or (ii) may be replaced by (CH2)nR4, as defined in formula(l) and in relation to the specific examples of EP-A-501322. The invention also provides novel compounds within formula (I) having
X1-(CH2)x-X2 as O-(CH2)2-CH2, in particular those wherein the side chain Z is of sub-formula (a) or (c).
The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto glutaric, α-glycerophosphoric, and glucose-1 -phosphoric acids.
Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds Rx-T wherein Rx is C1-6 alkyl, phenyl- C1-6 alkyl or C5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of Rx include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.
Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form
pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
It will also be realised that the (CH2)n2 moiety in compounds of formula (I) wherein Z is (b), may adopt an α or β or configuration with respect to the fused azabicyclic moiety. The compounds of formula (I) wherein CO-Y is an ester or amide linkage are prepared by conventional coupling of the Z moiety with the appropriate acid. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A, EP-A-36269 and EP-A-289170 (Beecham Group p.l.c). When CO-Y is replaced by a heterocyclic bioisostere, suitable methods are described in EP-A-328200 (Merck Sharp & Dohme Limited). Reference is also made to EP-A-501322 (Glaxo Group Limited).
Aza(bi)cyclic side chain intermediates are known compounds or may be prepared according to the methods described in PCT/GB92/01519 and /01612 (SmithKline Beecham p.l.c).
The compounds of the present invention are 5-HT4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic agent induced emesis. Specific cardiac 5-HT4 receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A.J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method).
Anxiolytic activity is likely to be effected via the hippocampus (Dumais et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test. Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT4 receptors, and hence that administration of a 5-HT4 antagonist is of potential benefit in relieving a migraine attack.
The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Such compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges,
reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.
Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol;
preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral liquid preparations are usually in the form of aqueous or oily
suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
The oral compositions may be prepared by conventional methods of blending, filling ortabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local
anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention. The invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal.
However, a unit dose for a 70kg adult will normally contain 0.05 to 1000mg for example 0.5 to 500mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
No adverse toxicological effects are indicated within the aforementioned dosage ranges.
The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastrooesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine. The following Examples illustrate the preparation of compounds of formula (I); the following descriptions relate to intermediates.
A preferred compound corresponds to any example, but wherein there is an amino substituent in the 4-position and a chloro substituent in the 5-position of the benzoic acid nucleus depicted in formula (I). Examples
R1 R2 R3 X1/X2 Y
E1 H H H O-(CH2)2-CH2 O
E2 H H H O-CH2-CH2 O
E3 H Cl H O-(CH2)2-CH2 O
E4 H H H O-CH(CH3)2-(CH2)2 O
E5 H Cl H O-CH(CH3)2-CH2 O
E6 NH2 Cl H O-(CH2)2-CH2 O
E7 H Cl H O-(CH2)2-CH2 O
E8 H Cl H O-(CH2)2-CH2 NH
E9 H Cl H O-CH(CH3)2-(CH2)2 O
E10 H H H S-(CH2)2-CH2 O
E11 H Br H S-(CH2)2-CH2 O
E12 NH2 Cl H 0-(CH2)2-CH2 NH Example 1
(1-Butyl-4-piperidyl)methyl-[2H]-3,4-dihydro-1-benzopyran-8-carboxylate
(E1 )
To a stirred solution of [2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (0.3g) in dichloromethane (15ml) at 0°C under nitrogen, was added oxalyl chloride (0.16 ml) and dry dimethylformamide (3m drops). After 1 hour, the solvents were evaporated under reduced pressure. The residual acid chloride was dissolved in dry THF (20 ml) and added dropwise to a solution of the lithium anion of 1-butyl-4-piperidinemethanol in dry THF, prepared by treating a solution of 1-butyl-4-piperidinemethanol (0.29g) in dry THF (20ml) with butyllithium (1.1 ml of a 1.6 molar solution in hexane), at 0°C under nitrogen for 15 minutes. After stirring at ambient temperature overnight, the reaction mixture was diluted with water, the volatile solvent was evaporated under reduced pressure, and the product was extracted into dichloromethane. The organic phase was dried (Na2SO4) and the solvent was evaporated under reduced pressure. The residue was chromatographed through a short flash silica column using an increasing proportion of methanol in chloroform (1%, 2%). The product was isolated as the hydrochloride salt from IPA/Et2O to give the title compound (177mg). mp 166-8°C. 1 H NMR 250MHz (CDCI3) (free base) δ: 7.62(d,1 H), 7.19(d,1 H), 6.85(t,1 H), 4.30(t,2H), 4.15(d,2H), 3.02(d,2H), 2.83(t,2H), 2.45-2.25(m,2H), 2.1-1.9(m,4H), 1.9-1.65(m,3H), 1.6-1.2(m,6H), 0.92(t,3H) Example 2
(1-Butyl-4-piperidyl)methyl-2,3-dihydrobenzofuran-7-carboxylate hydrochloride (E2)
To a stirred solution of 2,3-dihydrobenzofuran-7-carboxylic acid (D1 ) (0.2g) in dichloromethane (15ml) at 0°C under nitrogen was added oxalyl chloride (0.12ml) and dry dimethylformamide (3 drops). After 1 hour the solvents were evaporated under reduced pressure. The residual acid chloride was dissolved in dichloromethane (15ml) and treated with a solution of 1-butyl-4-piperidine methanol (0.21 g) in dichloromethane (10ml) and triethylamine (0.19ml). After stirring at ambient temperature overnight, the reaction mixture was washed with saturated NaHCO3 and the organic phase was dried (Na2SO4). The solvent was evaporated under reduced pressure and the residue chromatographed through a short flash silica column, eluting with increasing proportions of methanol in chloroform (1%, 2%). The product was isolated as the hydrochloride salt from IPA/Et2O to give the title compound (84 mg). mp 187-9ºC 1H NMR 250MHz (CDCI3) (free base) δ: 7.72(d,1 H), 7.35(d,1H), 6.88(t,1 H), 4.72(t,2H), 4.19(d,2H), 3.22(t,2H), 3.1-2.9(d,2H), 2.5-2.25(m,2H), 2.1 -1.2(m, 11 H), 0.92(t,3H)
Example 3
(1-Butyl-4-piperidyl)methyl-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylate (E3)
Following the procedure outlined in Example 1 (except that methyllithium was used in a place of n-butyllithium), 6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (300 mg) was converted to the title compound (143 mg, 28%). 1 H NMR 250 MHz (CDCI3) δ: 7.55 (s, 1 H), 7.15 (s, 1 H), 4.29 (t, 2H), 4.15 (d, 2H), 3.05 (brd, 2H), 2.80 (t, 2H), 2.5-2.25 (m, 2H), 2.18-1.10 (m, 13H), 0.94 (t, 3H) Example 4
2,2-Dimethyl-[2H]-3,4-dihydro-1-benzopyran-8-(1-butyl-4-piperidyl)methylcarboxylate hydrochloride (E4) To a solution of 2,2-dimethyl-[2H]-3,4-dihydro- 1-benzopyran-8-carboxylic acid (EP-A-307172) (300 mg) in acetonitrile (20 ml) was added N, N'-carbonyldiimidazole (236mg). Stirring was continued at ambient temperature for 1 h. The solvent was concentrated in vacuo to afford crude imidazolide. Methyllithium (1.5M in diethyl ether, 0.97 ml) was added dropwise to a cooled (0°C) solution of 1-butyl-4-piperidinemethanol (250 mg) in dry THF (10 ml) under a nitrogen atmosphere. Stirring was continued at room temperature for 10 min. A solution of the imidazolide in dry THF (10ml) was added and stirring continued overnight. Water was added and the solvent concentrated in vacuo. The residue was partitioned between chloroform and water. The organic phase was dried (Na2SO4), filtered and concentrated. The residue was chromatographed on silica using chloroform and ethanol as eluant to afford pure ester (471 mg) as an oil. Treatment with ethereal HCI and trituration of the resultant gum with diethyl ether gave title compound as a solid. 1H NMR 250 MHz (CDCI3) δ: 7.60(d,1 H), 7.19(d,1 H), 6.82(t,1 H), 3.99(d,2H), 2.93-3.03(m,2H), 2.81 (t,2H), 2.28-2.37(m,2H), 1.61-2.02(m,7H), 1.23-1.56(m,12H inc s,6H), 0.94(t,3H)
Example 5
7-(1-Butyl-4-piperidyl)methyl-5-chloro-2,3-dihydro-2,2-dimethylbenzofurancarboxylate (E5)
Following the procedure outlined in Example 4, 5-chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid was converted to the title compound. mp 225-6°C (hydrochloride salt) 1H NMR 250MHz (CDCI3) (free base) δ: 7.65(d,1 H), 7.22 (d,1 H), 4.12(d,2H), 2.92-3.11 (m,4H incl. s2H), 2.28-2.38 (m,2H), 1.22-2.0 (m, 17H inc s,6H), 0.92 (t,3H)
Example 6 (1-Butyl-4-piperidyl)methyl-5-amino-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylate hydrochloride (E6)
Following the procedure outlined in Example 4, 5-amino-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (D4) (200mg) was converted to the title compound (68mg 19%). mp 209-213°C
1 H NMR 250 MHz (CDCI3) (free base) δ: 7.7(s,1 H),- 4.39(brs, 2H), 4.22(t,2H), 4.10(d,2H), 3.05(brd,2H), 2.6-2.25(m,4H), 2.2-1.93(m,4H), 1.9-1.68(m,3H), 1.65-1.2(m,6H), 0.92(t,3H) Example 7
(1-Piperidyl)ethyl-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylate hydrochloride (E7)
Following the procedure outlined in Example 1 , except that MeLi was used in place of butyllithium, 6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (390mg) was converted to the title compound (182mg, 28%) mp 185-7ºC.
1 H NMR 250 MHz (CDCI3) (free base) δ: 7.58(s,1H), 7.15(s,1H), 4.4(t,2H), 4.29(t,2H), 2.88-2.65(m,4H), 2.6-2.35(m,4H), 2.15-1.9(m,2H), 1.7-1.3(m,6H)
Example 8
(1-Butyl-4-piperidyl)methyl-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxamide hydrochloride (E8)
A solution of 6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid
(200mg) in dry dichloromethane (6ml) was treated with oxaiyl chloride (0.13 ml) and dry dimethylformamide (2 drops) under nitrogen. After stirring for four hours at ambient temperature the solvent was evaporated under reduced pressure. The resulting acid chloride was dissolved in dry dichloromethane (6ml) and added to a stirring solution of 1-butylpiperidin-4-ylmethylamine (160mg) in dry dichloromethane (5ml) containing triethylamine (0.14 ml). After stirring at ambient temperature overnight under nitrogen, the reaction mixture was washed with NaHCO3 and the organic phase dried over
Na2SO4. The solvent was evaporated under reduced pressure to give the product which was purified using column chromatography (SiO2,
methanol/chloroform), and converted to the hydrochloride salt (E61) (138mg, 37%) mp 227-9°C. 1H NMR 250 MHz (CDCI3) (free base) δ: 7.98(s,1 H), 7.12(s,1 H), 4.35(t,2H), 3.35(t,2H), 3.08(brd, 2H), 2.85(t,2H), 2.5-2.3(m,2H), 2.2-1.92(m,4H), 1.9-1.2(m,9H), 0.92(t,3H)
Example 9
6-Chloro-2,2-dimethyl-[2H]-3,4-dihydro-1-benzopyran-8-(1-butyl-4-piperidyl)methyl carboxylate hydrochloride (E9)
Following the procedure outlined in Example 4,6-chloro-2,2-dimethyl-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (D5) (1g) was converted to the title compound (310mg)
1H NMR 250 MHz (CDCI3) (free base) δ: 7.55(d,1 H), 7.16(d,1 H), 4.13(d,2H), 2.98(bd, 2H), 2.79(t,2H), 2.32(t,2H), 1.68-2.00(m,7H), 1.24-1.54(m,12H inc s,6H), 0.92(t,3H)
Example 10 (1-Butyl-4-piperidyl)methylthiochroman-8-carboxylate (E10)
This was prepared according to the general method described in Example 1. Thus thiochroman-8-carboxylic acid (0.160g, 0.825 mmol) (D6) was converted to the title compound (0.145g, 53%) which was subsequently transformed into its hydrochloride salt m.pt 157-158°C.
1H NMR (250 MHz, CDCI3) (free base), δ: 7.82 (d, 1 H), 7.17 (d, 1 H), 7.00 (t, 1 H), 4.15 (d, 2H), 3.00 (m, 4H), 2.87 (t, 2H), 2.38 (t, 2H), 2.20-1.95 (m, 5H), 1.80 (m, 2H), 1.50 (m, 4H), 1.30 (m, 2H), 0.90 (t, 3H). Example 1 1
(1-Butyl-4-piperididyl)methyl-6-bromothiochroman-8-carboxylate (E11 ) This was prepared according to the general method described in Example 1. Thus 6-bromothiochroman-8-carboxylic acid (0.318g, 1.17mmol) (D7) was converted to the title compound (0.217g, 44%) which was subsequently transformed into its hydrochloride salt. m.pt. 197-198°. 1 H NMR (200 MHz, CDCI3) (free base) δ: 7.90 (d, 1 H), 7.30 (d, 1 H), 4.20 (d, 2H), 3.00 (m, 4H), 2.88 (t, 2H), 2.32 (t, 2H), 2.10 (m, 2H), 2.00-1.70 (m, 4H), 1.55-1.20 (m, 7H), 0.92 (t, 3H).
Example 12
5-Amino-(1-butyl-4-piperidyl)methyl-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxamide (E12)
A solution of 5-amino-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (D4, 200mg ) in acetonitrile (6ml ) was treated with bis-carbonyldiimidazole (171 mg) and the resulting solution was stirred at room temperature for 2 hours. A solution of (1-butyl-4-piperidyl) methylamine (150mg) in acetonitrile (10ml) was added and the reaction mixture was stirred at room temperature for 15 hours. The solvent was removed in vacuo and the residue partitioned between water and dichloromethane. The
dichloromethane layer was removed and the aqueous extracted further with dichloromethane. The organic extracts were combined and washed with water, then dried (Na2SO4) and concentrated to give a yellow gum that was purified by column chromatography on silica using CHCI3 with increasing quantities of MeOH as eluant to give the title compound as an off white solid , 30mg mp 65-6°C. 1 H NMR (250 MHz CDCI3) δ: 8.0 (S,1 H), 7.96-7.8 (m,1 H), 4.45-4.15 (m,4H.) 3.32 (t,2H), 3.02 (d,2H), 2.53 (t, 2H), 2.39 (t,2H), 2.2-1.9 (m,4H), 1.86-1.15(m,9H), 0.92 (t,3H) Descriptions
Description 1 (intermediate for Example 2) [2H]-3,4-Dihydro-1-benzopyran-8-carboxylic acid
Following the procedure outlined in EP-A-307172 Example 15, [2H]-3,4-dihydro-1-benzopyran (0.85g) was converted to the title compound (D1) (0.77g)
1 H NMR (200MHz)(CDCI3) δ: 8.0(d,1 H), 7.3(d, 1 H), 7.0(t,1 H), 4.45(t,2H), 2.89(t,2H), 2.25-2.0(m,2H)
Description 2 (intermediate for Example 2)
2,3-Dihydrobenzofuran-7-carboxylic acid
Following the procedure outlined in EP-A-307172, Example 15, 2,3-dihydrobenzofuran (0.59g) was converted to the title compound (D2) (0.41 g)
1 H NMR 250MHz (CDCI3) δ: 7.82(d,1H), 7.44(d,1H), 6.96(t,1H), 4.80(t,2H), 3.30(t,2H)
Description 3 (intermediate for Example 3)
6-Chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid A solution of [2H]-3,4-dihydro-1-benzopyran-8-carbαxylic acid (D1 ) (150mg) in glacial acetic acid (10ml) was treated with a solution of 1.3 equivalents of chlorine (80mg) in glacial acetic acid (2.8 mis) dropwise with ice-cooling.
After stirring overnight at ambient temperature the solvents were evaporated under reduced pressure, and the residue triturated with diethyl ether to give the title compound (D3) (64mg, 36%).
1 H NMR 200 MHz (CDCI3) δ: 10.78 (brs, 1 H), 7.95 (s, 1 H), 7.25 (s, 1 H), 4.45 (t, 2H), 2.88 (t, 2H), 2.25-2.0 (m, 2H)
Description 4 (intermediate for Example 6) a) Methyl(4-acetylamino-2-propargyloxy)benzoate
A solution of methyl-4-acetylamino-2-hydroxybenzoate (prepared as described in EP-A-234872) (5 g) in a mixture of dry tetrahydrofuran (100 ml) and dry dimethylformamide (150 ml) was treated with 1 equivalent of sodium hydride (0.72g of an 80% dispersion in oil). After stirring for 1 hour under nitrogen, 2.5 equivalents of propargylbromide (5.33 ml) were added, and the mixture was heated under reflux for three days. The solvents were
evaporated under reduced pressure and the residue partitioned between 10% sodium hydroxide and ethyl acetate. The organic phase was dried over Na2Sθ4 and evaporated under reduced pressure to give a red oil which, after trituration with 60°-80° petrol-ether gave the title compound as a light tan powder (4.95g, 84%)
1 H NMR 200 MHz (CDCI3) δ: 7.91 (brs, 1 H), 7.81 (d,1 H), 7.68(s,1 H), 7.05(d,1 H), 4.78(d,2H), 3.86(s,3H), 2.54(m,1 H), 2.2(s,3H) b) Methyl(5-acetamido-[2H]-1-benzopyran)-8-carboxylate
A solution of methyl(4-acetamido-2-propargyloxy)benzoate (6.38g) in 1 ,2-dichlorobenzene (65ml) was heated under reflux under nitrogen for 60 hours. The solvent was evaporated under reduced pressure and the residue purified on a silica column, eluting with methanol/chloroform, to give the title compound as a tan solid (3.47g, 54%)
1H NMR 200 MHz (CDCI3) δ: 7.79(brs, 1 H), 7.64(d,1H), 7.3(d,1H), 6.46(d,1 H), 5.85(m,1 H), 4.75(brs,2H), 3.85(s,3H), 2.20(s,3H) c) Methyl(5-acetamido-[2H]-3,4-dihydro-1-benzopyran)-8-carboxylate
A solution of methyl (5-acetamido-[2H]-1-benzopyran)-8-carboxylate (D23) (770mg) in ethanol, was hydrogenated over 10% palladium on charcoal at atmospheric pressure for 1.25 hours. The reaction mixture was filtered and the filtrate evaporated under reduced pressure to give the title compound as a white powder (670 mg, 86%)
1 H NMR 250 MHZ (CDCI3) δ: 7.68(d,1 H), 7.49(brs, 1 H), 7.19(brs,1H), 4.22(t,2H), 3.88(s,3H), 2.62(t,2H), 2.20(s,3H), 2.1-1.96(m,2H) d) Methyl(5-acetamido-6-chloro-[2H]-3,4-dihydro-1-benzopyran-8-carboxylate
Following the procedure outlined in Description 3, methyl (5-acetamido-[2H]-3,4-dihydro-1-benzopyran)-8-carboxylate (660mg) was converted to the title compound which was isolated as a light tan powder (525mg, 70%) 1 H NMR 250 MHz (CDCI3) δ: 7.7(s,1 H), 7.15(s,1 H), 4.29(t,2H), 3.89(s,3H), 2.70(t,2H), 2.25(s,3H), 2.05- 1.9(m,2H) e) 5-Amino-6-chloro-[2H]-3,4-dihydro-1-benzopyran-S-carboxylic acid A solution of methyl (5-acetamido-6-chloro-[2H]-3,4-dihydro-1-benzoρyran-8-carboxylate (1.015g) in ethanol (20 ml) water (10 ml) and 10% sodium hydroxide (30 ml) was heated under reflux for 24 hours, then cooled and treated with concentrated hydrochloric acid (until pH 2) and the resulting precipitate was filtered off to give the title compound (D4) (427mg, 52%)
1 H NMR 250 MHZ (CDCI3) δ: 7.85(s,1H), 4.34(t,2H), 2.54(t,2H), 2.25-2.0(m,2H)
Description 5 (intermediate for Example 9) 6-Chloro-2,2-dimethyl-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid Following the procedure outlined in Description 3, 2,2-dimethyl-[2H]-3,4-dihydro-1-benzopyran-8-carboxylic acid (EP-A-307172) (2.41 g) gave the title compound (D5) (2.68g). M+ 240 (E1)
Description 6 (intermediate for Example 10) a) Methylthiochroman-4-one-8-carboxylate β-(2-carbomethoxythiophenoxy) propionic acid (6.00g, 0.025mol) (I.W. Still and M.J. Thomas J.Org. Chem 1968, 2733) was added slowly to ice cooled cone, sulphuric acid (75ml) with stirring. After 21 h, the reaction mixture was poured into ice water and then made alkaline using solid sodium hydrogen carbonate. The resultant suspension was then extracted with CH2Cl2(3X). The combined organic layers were then dried (Na2SO4), and evaporated under reduced pressure to give an orange oil which was dried in vacuo and crystallised on standing to give (2.40g, 43%). b) Methylthiochroman-4-ol-8-carboxylate
Methylthiochroman-4-one-8-carboxylate (0.500g, 2.25mmol) was dissolved with stirring in ethanol (20 ml). After 1 h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between ethyl acetate and water. The aqueous layer was then extracted with ethyl acetate (1X) and the combined organic layers were dried (Na2Sθ4) and evaporated under reduced pressure to give a yellow oil, which was purified by silica-gel chromatography (1 :1 Pentane:EtOAc as eluant) to give the title compound as a colourless oil (0.499g, 99%) 1 H NMR (200 MHz, CDCI3) δ: 7.95 (dd, 1 H), 7.55 (dd, 1 H), 7.12 (t, 1 H), 4.87 (m, 1 H), 3.92 (s, 3H) 3.23 (m, 1 H), 2.88 (m, 1 H), 2.37 (m, 1 H), 2.08 (m, 1 H), 1.92 (d, 1 H). c) Methyl-2H-thiochromene-8-carboxylate
Methyl thiochroman-4-ol-8-carboxylate (0.337g, 1.50 mmol) was dissolved in toluene (25ml) and was treated with p-toluenesulphonic acid (0.028g, 0.15 mmol). The mixture was then heated to reflux with stirring. After 2h, the reaction mixture was allowed to cool and was washed with sodium hydrogen carbonate solution. The aqueous layer was then extracted with EtOAc (1X), and the combined organic layers were dried (Na2SO4) and evaporated under reduced pressure to give a pale yellow oil which was purified by silica-gel chromatography (pentane: Et2O 2:1 as eluant) to give the title compound (D2b) as a pale yellow oil (0.270g, 87%)
1 H NMR (200 MHz, CDCI3, δ: 7.80 (dd, 1 H), 7.20 (dd, 1 H), 7.10 (t, 1 H), 6.52 (d, 1 H), 6.02 (m, 1 H), 3.92 (s, 3H), 3.48 (dd, 1 H). d) Methylthiochroman-8-carboxylate
Methyl-2H-thiochromene-8-carboxylate (1.83g, 8.88 mmol) was dissolved in ethanol (100ml) and treated with 10% PdC (1.5g). The mixture was then hydrogenated at atmospheric pressure at room temperature. After 19h the reaction mixture was filtered through celite and evaporated under reduced pressure to give a colourless oil which was dried in vacuo to give the title compound (1.25g, 68%) 1 H NMR (200 MHz, CDCI3), δ 7.80 (d, 1 H), 7.62 (d, 1 H), 6.97 (t, 1 H), 3.89 (s, 3H), 2.97 (t, 2H), 2.87 (t, 2H), 2.12 (m, 2H). e) Thiochroman-8-carboxylic acid Methylthiochroman-8-carboxylate (0.220g, 1.05mmol) was dissolved in ethanol (5ml) and treated with 10% sodium hydroxide solution (10ml). The mixture was then heated to reflux with stirring. After 5h, the reaction mixture was allowed to cool. The ethanol present was then removed by evaporation under reduced pressure. The aqueous residue was then washed with CH2CI2 (2X) before being acidified to pH1 using 5M HCI. The resultant pale yellow precipitate was then filtered off and dried in vacuo to give the title compound (0.156g, 76%) (D6).
1 H NMR (200 MHz, CD3OD) δ: 7.80 (d, 1 H), 7.20 (d, 1 H), 7.00 (t, 1 H), 2.90 (m, 4H), 2.08 (m, 2H). Description 7 (intermediate for Example 11 ) a) Methyl-6-bromothiochroman-8-carboxylate A solution of methylthiochroman-8-carboxylate (0.300g, 1.44 mmol) (D6a) in dichloromethane (20ml) was treated with bromine (0.106 ml, 2.07 mmol) and the reaction mixture left at room temperature. After 4 days the reaction mixture was washed with sodium metabisulphile solution. The organic layer was then dried (Na2SO4) and evaporated under reduced pressure to give the title compound as a colourless oil (0.340g, 82%).
1 H NMR (250 MHz, CDCI3) δ: 7.92 (d, 1 H), 7.30 (d, 1 H), 3.92 (s, 3H), 3.00 (t, 2H), 2.88 (t, 2H), 2.10 (m, 2H). b) 6-Bromothiochroman-8-carboxylic acid
This was prepared according to the general method described in Description 6e). Thus, methyl-6-bromo-thiochroman (0.325g, 1.13mmol) was converted to the title compound (0.306g, 99%) (D7).
1 H NMR (200MHz, CD3SOCD3) : 13.25 (brs, 1 H), 7.82 (d, 1 H), 7.50 (d, 1 H), 2.92 (m, 4H), 2.00 (m, 2H).
5-HT4 RECEPTOR ANTAGONIST ACTIVITY
1) Guinea pig colon
Male guinea-pigs, weighing 250-400g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3cm long, are obtained from the distal colon region. These are suspended under a 0.5g load in isolated tissue baths containing Krebs solution bubbled with 5% CO2 in O2 and maintained at 37°C. In all experiments, the Krebs solution also contains methiothepin 10-7M and granisetron 10-6M to block effects at 5-HT1, 5-HT2 and 5-HT3 receptors.
After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 15min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 4 70% maximum(10-9M approx). The tissue is then alternately dosed every 15min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT4 receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, plC50 values are determined, being defined as the-log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor antagonist.
Compounds were generally active in the range of concentrations of the order of plC50=7 or more, E3, E8 and E12 showing particularly good activity.
2) Piglet Atria
Compounds were tested in the piglet spontaneous beating screen (Naunyn-Schmiedeberg's Arch. Pharmacol 342, 619-622). pKB (-log10 Kg) value for the compound of Examples 3 and 7 were 9.8 and 7.7 respectively. 3) Rat oesophagus
Rat oesophageal tunica muscularis mucosae is set up according to Baxter et. al. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991 ). The inner smooth muscle tube of the muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% 02/5% CO2) Tyrodes solution at 37°C. All experiments are performed in pargyline pre-treated preparations (100μM for 15 min followed by washout) and in the presence of ***e (30μM). Relaxant responses to 5-HT are obtained after pre-contracting the oesophagus tissue with carbachol (3μM).
4) 5-HT-induced motility in dog gastric pouch
Compounds are tested in the in vivo method described in "Stimulation of canine motility by BRL 24924, a new gastric prokinetic agent", Bermudez et al, J. Gastrointestinal Motility, 2(4), 281-286.
The compound E3 showed inhibition at a dose of 10μg kg- 1.

Claims

Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof
in which X1-(CH2)x-X2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring
wherein:
one of X1 and X2 is O, S or CH2 and the other is CH2;
x is 1 , 2 or 3;
R1 is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
R2 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio; R3 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 and R5 are independently hydrogen or C1-6 alkyl;
Y is O or NH;
Z is of sub-formula (a), (b) or (c):
wherein
n1 is 1 , 2, 3 or 4; n2 is 1 or 2; n3 is 2, 3, 4 or 5;
q is 0, 1 , 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
Ra is hydrogen or a lipophilic group, such as C1-12 alkyl or aralkyl;or
Ra is (CH2)r-R10 wherein r is 2 or 3 and R10 is selected from cyano,
hydroxyl, C1-6 alkoxy, phenoxy, C(O) C1-6 alkyl, COC6H5, -CR1 1 R12, NR11 COR12, SO2NR1 1 R12 or NR11 SO2R12 wherein R1 1 and R12 are hydrogen or C1-6 alkyl; and
R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and
R9 is hydrogen or C1-10 alkyl;
or a compound of formula (I) wherein the CO-Y linkage is replaced by a
heterocyclic bioisostere.
2. A compound according to claim 1 wherein R1 is hydrogen or amino.
3. A compound according to claim 1 or 2 wherein R2 is hydrogen or halo.
4. A compound according to claim 1 , 2, or 3 wherein R3 is hydrogen or halo.
5. A compound according to claim 1 , 2, 3 or 4 wherein X1-(CH2)x-X2 is O-(CH2)2-CH2, O-(CH2)3-CH2, O-CH2-CH2, or corresponding values wherein X1 = X2 = CH2, wherein any of the methylene linkages are optionally mono- or di-substituted by C1-6 alkyl groups, such as methyl.
6. A compound according to any one of claims 1 to 5 wherein Y is O or NH.
7. A compound according to any one of claims 1 to 6 wherein Z is of sub-formula (a) and (CH2)n1 is attached at a carbon atom of the azacycle.
8. A compound according to claim 7 wherein Z is N-substituted
4-piperidylmethyl.
9. A compound according to claim 8 wherein the N-substituent is C2 or greater alkyl, or optionally substituted benzyl.
10. A compound according to claim 1 selected from the compounds E1 to E12 inclusive, as described herein, including pharmaceutically acceptable salts thereof.
11. A process for preparing the ester or amide compounds according to claim 6, which comprises reacting an appropriate benzoic acid derivative with an appropriate alcohol or amine.
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, and a pharmaceutically acceptable carrier.
13. A compound according to claim 1 for use as an active therapeutic substance.
14. The use of a compound according to claim 1 in the manufacture of a medicament for use as a 5-HT4 receptor antagonist.
15. The use according to claim 14 for use as a 5-HT4 antagonist in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
EP93917412A 1992-02-06 1993-02-01 Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists Withdrawn EP0625149A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB929202510A GB9202510D0 (en) 1992-02-06 1992-02-06 Pharmaceuticals
GB9202510 1992-02-06
GB929215499A GB9215499D0 (en) 1992-07-21 1992-07-21 Pharmaceuticals
GB9215499 1992-07-21
GB9221446 1992-10-13
GB929221446A GB9221446D0 (en) 1992-10-13 1992-10-13 Pharmaceuticals
GB929225788A GB9225788D0 (en) 1992-12-10 1992-12-10 Pharmaceuticals
GB9225788 1992-12-10
PCT/GB1993/000214 WO1993016072A1 (en) 1992-02-06 1993-02-01 Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Publications (1)

Publication Number Publication Date
EP0625149A1 true EP0625149A1 (en) 1994-11-23

Family

ID=27450819

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93917412A Withdrawn EP0625149A1 (en) 1992-02-06 1993-02-01 Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Country Status (8)

Country Link
EP (1) EP0625149A1 (en)
JP (1) JPH07503480A (en)
KR (1) KR950700288A (en)
AU (1) AU667874B2 (en)
CA (1) CA2129112A1 (en)
MX (1) MX9300616A (en)
NZ (1) NZ246915A (en)
WO (1) WO1993016072A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
WO1994008994A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
JPH07507290A (en) * 1992-05-23 1995-08-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Medications for the treatment of anxiety disorders
JPH07508276A (en) * 1992-06-27 1995-09-14 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Pharmaceutical products containing 5-HT↓4 receptor antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9305947A (en) * 1992-09-29 1994-06-30 Smithkline Beecham Plc ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9306311A (en) * 1992-10-13 1994-04-29 Smithkline Beecham Plc ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
EP0664794A1 (en) * 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
GB9303340D0 (en) * 1993-02-19 1993-04-07 Smithkline Beecham Plc Pharmaceuticals
GB9507882D0 (en) * 1995-04-18 1995-05-31 Pharmacia Spa Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
TR199800827T2 (en) * 1995-11-09 1999-02-22 Synthelabo 5-HT4, H3 reseptér ligandlarà olarak 5-fenil-3-(piperidin-4-il)-1,3,4-oksadiyazol-2(3H)-on trevleri.
FR2745574B1 (en) * 1996-03-04 1998-04-03 Synthelabo 5-PHENYL-3- (PIPERIDIN-4-YL) -1, 3, 4-OXADIAZOL-2 (3H) -ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
FR2762316B1 (en) * 1997-04-18 1999-12-17 Sanofi Synthelabo 5-ARYL-3- (8-AZABICYCLO [3.2.1] OCTAN-3-YL) -1,3,4- OXADIAZOL-2 (3H) -ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2763068B1 (en) * 1997-05-06 1999-06-04 Synthelabo DERIVATIVES OF 3- (PYRROLIDIN-3-YL) -1,3,4-OXADIAZOL-2 (3H) -ONE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
ES2283132T3 (en) * 1998-09-10 2007-10-16 F. Hoffmann-La Roche Ag DIHYDROBENZODIAXIN CARBOXAMIDE AND KETONE DERIVATIVES AS RECEIVING ANTAGONISTS OF 5-HT4.
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
DE602004009069T2 (en) 2003-06-19 2008-06-19 Janssen Pharmaceutica N.V. 4- (AMINOMETHYL) -PIPERIDINBENZAMIDES AS 5HT4 ANTAGONISTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186969A (en) * 1983-04-08 1984-10-23 Yoshitomi Pharmaceut Ind Ltd Benzofurancarboxamide and benzopyranecarboxamide derivative
CA1297877C (en) * 1983-12-22 1992-03-24 Daniel Lednicer Benzofurancarboxamides useful as antiemetic or antipsychotic agents
US4888353A (en) * 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
SE8503055D0 (en) * 1985-06-19 1985-06-19 Astra Laekemedel Ab PIPERONYLCARBOXAMIDO DERIVATIVES
FR2593504B1 (en) * 1986-01-30 1988-12-09 Ile De France NOVEL DIHYDROBENZOFURANNE - AND CHROMANE - CARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS NEUROLEPTICS
JPS62234083A (en) * 1986-02-28 1987-10-14 アーバモント　インク　ディビーエイ　アドリヤ　ラボラトリーズ Carboxamides useful as antiemetic and mental disease remedy
EP0314483A1 (en) * 1987-10-29 1989-05-03 Erbamont, Inc. Preparation of benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US5122361A (en) * 1989-04-17 1992-06-16 Trustees Of The University Of Pennsylvania Dopamine receptor ligands and imaging agents
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
JPH04225954A (en) * 1990-05-02 1992-08-14 Yoshitomi Pharmaceut Ind Ltd Amide compound, its pharmaceutical use and new 1-substituted pyrrolidinemethylamines
US5114947A (en) * 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
GB9028105D0 (en) * 1990-12-27 1991-02-13 Erba Carlo Spa Process for the preparation of substituted benzofuran derivatives
JPH05163270A (en) * 1991-05-13 1993-06-29 Yoshitomi Pharmaceut Ind Ltd Benzofuran carboxamide compound
JPH04364181A (en) * 1991-06-04 1992-12-16 Yoshitomi Pharmaceut Ind Ltd Benzofurancarboxamide compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9316072A1 *

Also Published As

Publication number Publication date
KR950700288A (en) 1995-01-16
CA2129112A1 (en) 1993-08-19
NZ246915A (en) 1996-05-28
AU3457293A (en) 1993-09-03
AU667874B2 (en) 1996-04-18
MX9300616A (en) 1993-09-01
WO1993016072A1 (en) 1993-08-19
JPH07503480A (en) 1995-04-13

Similar Documents

Publication Publication Date Title
EP0625149A1 (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
EP0604494B1 (en) 5-ht4 receptor antagonists
AU680453B2 (en) Piperidine derivatives as 5-HT4 receptor antagonists
US20060094702A1 (en) 5-HT4 receptor antagonists
US5708174A (en) Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
US5726187A (en) N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
AU682317B2 (en) Heteroaryl compounds used as pharmaceuticals
EP0629198A1 (en) Nitrogen containing heterocyclic compounds useful as pharmaceuticals
WO1993008187A1 (en) Imidazopyridines and indolizines as 5-ht4 antagonists
WO1994017071A1 (en) Tricyclic heterocyclic compounds as 5-ht4 receptor antagonists
US6127379A (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
WO1994029298A1 (en) 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
EP0712406B1 (en) Condensed indole derivatives as 5-ht 4-receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19970228

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APCB Communication from the board of appeal sent

Free format text: ORIGINAL CODE: EPIDOS OBAPE

APCB Communication from the board of appeal sent

Free format text: ORIGINAL CODE: EPIDOS OBAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010125

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012351

Country of ref document: HK

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE